Inhibikase Therapeutics IKT Balance Sheet (2020-2026)

NASDAQ IKT
$2.50 -0.02 (-0.79%)
As of: Sep 4, 2026 · 3:59 PM EDT
Reported Financials

Inhibikase Therapeutics Quarterly Balance Sheet

Periods 26 quarters
Latest Jun 2026

Inhibikase Therapeutics reported total assets of $163.59M and total liabilities of $10.26M for the quarter ended Jun 2026, up 84.1% year over year. This balance sheet covers 26 quarters of results from Mar 2020 through Jun 2026, standardized by Business Quant from the company’s SEC filings.

Balance Sheet Mar2020 Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026 Jun2026
Assets
Current Assets
Cash & EquivalentsCash & Equiv.
44.85M40.75M36.61M32.21M5.78M7.19M3.96M1.91M14.86M9.17M2.35M3.09M0.91M56.49M73.44M77.74M38.27M139.22M49.57M31.21M
Short-term InvestmentsInvestments (Current)
20.75M15.86M21.76M19.03M1.97M4.09M7.40M4.85M2.33M41.05M19.74M9.92M39.05M39.54M120.80M127.81M
Cash & Current Investments
44.85M40.75M36.61M32.21M26.53M23.05M25.72M20.94M16.83M13.25M9.75M7.94M3.24M97.54M93.18M87.67M77.32M178.76M170.37M159.02M
Receivables - NetNet Receivables
0.11M0.05M0.01M0.01M0.04M0.06M0.08M
Receivables - OtherOther Receivables
0.22M
Receivables
0.11M0.05M0.01M0.01M0.04M0.06M0.08M
Prepaid Assets
0.54M1.50M1.17M0.92M0.93M1.12M0.92M0.54M0.37M0.74M0.85M0.36M0.28M0.83M0.93M0.68M0.62M1.00M1.29M2.35M
Current Assets
42.47M33.95M27.99M24.37M27.63M21.98M17.55M14.21M10.81M8.60M4.19M98.45M94.16M88.79M78.54M180.11M172.18M162.34M
Non-Current Assets
Property, Plant & Equipment (Net)PP&E (Net)
0.04M0.24M0.24M0.23M0.09M0.08M0.07M0.07M0.06M0.05M0.05M0.05M0.02M
Other Non-Current Assets
0.15M0.55M0.31M1.00M1.00M1.00M1.00M
Non-Current Assets
0.04M0.59M0.57M0.53M0.36M0.33M0.30M0.26M0.22M0.19M0.15M0.12M0.06M1.06M1.10M1.16M1.24M
Assets
45.87M42.47M38.39M33.99M28.58M24.94M28.16M22.35M17.88M14.51M11.07M8.83M4.38M98.60M94.28M88.85M79.59M181.20M173.33M163.59M
Liabilities
Current Liabilities
Accounts Payables
2.46M1.09M4.38M4.49M20.75M1.15M21.76M19.03M1.97M0.65M3.80M3.38M2.53M0.94M1.69M2.70M0.62M1.16M1.59M0.99M
Notes Payables
0.25M0.25M
Payables
2.71M1.34M4.38M4.49M20.75M1.15M21.76M19.03M1.97M0.65M3.80M3.38M2.53M0.94M1.69M2.70M0.62M1.16M1.59M0.99M
Accumulated Expenses
1.91M2.72M3.57M3.63M2.29M2.40M1.56M1.83M1.86M2.26M2.51M2.03M2.16M2.68M3.51M3.15M3.66M4.08M4.12M9.27M
Other Accumulated Expenses
0.01M0.01M0.02M0.01M3.07M0.01M2.66M2.73M2.74M0.10M0.03M0.01M0.01M0.08M0.13M0.07M0.12M0.21M0.11M0.04M
Short term Debt
0.14M0.15M0.15M0.15M0.15M0.15M0.15M0.15M0.15M0.11M0.07M0.04M
Current Deferred Revenue
0.02M0.02M
Total Current Liabilities
2.71M4.05M3.21M3.70M2.66M2.73M2.74M3.44M4.23M3.70M4.91M3.73M8.55M8.80M6.70M8.30M5.71M10.26M
Non-Current Liabilities
Capital Leases
0.23M0.21M0.18M0.15M0.12M0.09M0.06M
Non-Current Debt
0.25M0.25M0.38M
Minority Interest
58.40M106.60M
Other Non-Current Liabilities
4.44M0.40M0.40M
Total Non-Current Liabilities
4.29M4.12M5.31M9.86M
Total Liabilities
2.71M4.05M4.38M4.49M3.45M3.90M2.84M2.88M2.86M3.53M4.29M3.73M4.91M3.73M8.55M8.80M6.70M8.30M5.71M10.26M
Shareholder's Equity
Total Debt
0.50M0.50M0.14M0.15M0.15M0.15M0.15M0.53M0.15M0.15M0.15M0.11M0.07M0.04M
Common Equity
43.16M38.42M34.01M29.50M25.14M21.04M25.28M19.46M15.02M10.98M6.78M5.10M-0.53M94.87M85.73M80.05M72.90M172.90M167.62M153.33M
Liabilities and Shareholders Equity
45.87M42.47M38.39M33.99M28.58M24.94M28.16M22.35M17.88M14.51M11.07M8.83M4.38M98.60M94.28M88.85M79.59M181.20M173.33M163.59M
Retained Earnings
-24.78M-29.82M-34.46M-39.10M-43.59M-47.87M-52.35M-58.13M-62.72M-66.90M-71.55M-76.51M-82.29M-94.42M-108.10M-118.01M-129.95M-142.68M-159.10M-178.70M